In This Article:
Mach7 Technologies (ASX:M7T) First Half 2025 Results
Key Financial Results
-
Revenue: AU$17.7m (up 33% from 1H 2024).
-
Net loss: AU$1.87m (loss narrowed by 60% from 1H 2024).
-
AU$0.008 loss per share (improved from AU$0.019 loss in 1H 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Mach7 Technologies Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 20%.
Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Healthcare Services industry in Australia.
Performance of the Australian Healthcare Services industry.
The company's shares are up 3.5% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 1 warning sign for Mach7 Technologies you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.